UROLOGIX INC (OTCMKTS:ULGX) Sellers Reduced By 7.45% Their Shorts

June 27, 2018 - By Nicole Mills

Big Money Sentiment decreased to 0 in Q1 2018. It has change of Infinity, from 2017Q4’s Infinity. The ratio fall due to Urologix, Inc. positioning: 0 sold and 0 reduced. 0 funds bought stakes and 0 increased stakes. Investors holded 60,521 in 2017Q4 but now own 60,521 shares or 0.00% without change.
Moreover, Gemmer Asset Limited Co has 0% invested in Urologix, Inc. (OTCMKTS:ULGX). Mairs & Pwr invested in 20,000 shs.

Change of 7.45% for UROLOGIX INC (OTCMKTS:ULGX)’s shares shorted was registered. It was published in June by FINRA the 38,500 shares shorted on ULGX. The down change of 7.45% from 41,600 shares was reported. UROLOGIX INC (OTCMKTS:ULGX) has 286,700 shares average volume. It’ll cost 0 days for ULGX to restore its previous position.

ULGX touched $0.07311 during the last trading session after $0.00311 change.Currently Urologix, Inc. is after 0.00% change in last June 27, 2017. ULGX has 134,846 shares volume. ULGX underperformed the S&P 500 by 12.57%.

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States.The firm is valued at $1.56 million. The firm offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort.Currently it has negative earnings. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: